glp 1 pharmacology GLP-1 Receptor Agonist Services for Type 2 Diabetes and Obesity Drug Development Glucagon-like peptide 1 (GLP-1) -

ATTAIN-1 (orforglipron, 72 weeks): Discontinuation due to AEs: 5.3-10.3% (orforglipron) vs 2.7% placebo Key characteristics: GI profile is broadly similar to injectable GLP-1 agonists despite oral route Nausea rates are comparable to tirzepatide The oral formulation does not appear to worsen GI tolerability relative to SC injection Safety profile described as "consistent with injectable GLP-1 medicines" Ecnoglutide# Ecnoglutide is a cAMP-biased GLP-1 receptor agonist developed by Sciwind Biosciences

The pharmacologic effects of GLP-1 are noted in the next figure

More recently, dual and triple agonists targeting additional incretin and metabolic hormone receptors have demonstrated enhanced therapeutic potential, revolutionizing the landscape of MASLD treatment [11,12]

Its foundation is habit change, community engagement, and ongoing workshops, with GLP-1 prescriptions added as a complementary tool rather than the centerpiece

Non-peptidic oral GLP-1RAs may eventually reduce supply pressures because they do not require peptide synthesis or cold-chain storage, but this will depend on scalable, cost-efficient manufacturing pathways

10.1016/j.neuron.2017.09.043 [DOI] [PMC free article] [PubMed] [Google Scholar] Biddinger, J